Dexcom anticipates $5.20B-$5.25B 2026 revenue while authorizing another $1B buyback

• "Today, we reported third quarter revenue growth of 11% compared to the third quarter of 2025" (President, CEO & Director Jacob Leach), adding, "We once again gained share in the quarter" and "In the U.S., we again delivered strong revenue growth of 14% and captured share across the market" (President Leach).
• "We continue to expect CMS to announce a type 2 non-insulin coverage decision this year" (President Leach), and "we now expect CONNECT to do the same thing for the type 2 non-insulin population" after the trial showed "a 1.6% A1c improvement" and "a 0.9% difference" (President Leach).
• "During the third quarter, we launched a fully redesigned Stelo app" (President Leach) and said G7 15 Day adoption "leaves us on track to convert nearly 50% of our U.S. customer base to G7 15 Day by year-end"; he also noted, "we've already seen a 4- to 5-point improvement in 15 Day survivability" as updated adhesive rolls out (President Leach).
• "Ireland expands our manufacturing capacity and strengthens the resilience of our global supply network" (President Leach), adding the facility "recently initiated commercial production on schedule" (President Leach).
• "We recently promoted Jereme Sylvain to Chief Operating Officer in addition to his responsibilities as Chief Financial Officer" (President Leach).
• "For the third quarter of 2026, we reported worldwide revenue of $1.34 billion" (Executive VP, CFO, COO & Chief Accounting Officer Jereme Sylvain) and "Net income for the third quarter was $275 million or $0.73 per share" (Executive VP Sylvain).
• "We have now generated over $900 million of free cash flow through the first 3 quarters of the year" (Executive VP Sylvain) and "already execute[d] our Investor Day goal of repurchasing $1 billion of stock in 2026"; he added, "we are announcing another $1 billion share repurchase authorization" (Executive VP Sylvain).

Outlook

• "We are updating our revenue guidance to be in the range of $5.20 billion to $5.25 billion" (Executive VP Sylvain), and said the update "passes through the third quarter revenue outperformance, partially offset by approximately $5 million of incremental foreign exchange headwinds since last quarter" (Executive VP Sylvain).
• "For margins, we are maintaining our full year non-GAAP gross profit margin guidance at approximately 64%" (Executive VP Sylvain) and "increasing our non-GAAP operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%" (Executive VP Sylvain).
• "This also implies midpoint fourth quarter growth of 10%" (Executive VP Sylvain).

Financial Results

• "Worldwide revenue" was "$1.34 billion" with "U.S. revenue" of "$970 million" and "International revenue" of "$375 million" (Executive VP Sylvain).
• "Our third quarter gross profit was $875.3 million or 65.1% of revenue" (Executive VP Sylvain), who attributed margin performance to "continued manufacturing efficiencies, further progress in freight and quality management and a benefit from the continued ramp-up of G7 15 Day" (Executive VP Sylvain).
• "Operating income was $339.5 million or 25.3% of revenue" and "Adjusted EBITDA was $435.2 million or 32.4% of revenue" (Executive VP Sylvain).
• "Operating expenses were $535.8 million" (Executive VP Sylvain), who said margin expansion occurred "despite increased investment in Ireland" (Executive VP Sylvain).
• "We remain in a great financial position" with "approximately $1.8 billion of cash and cash equivalents" (Executive VP Sylvain).

Q&A

• Matthew Taylor, Jefferies: "comment on...overall category growth" and competitor "pricing headwinds"; President Leach: "nothing has changed in our view of the opportunity" and "Our active base growth is in the upper teens"; Executive VP Sylvain: "We haven't seen a degradation of pricing around the world" (President Leach; Executive VP Sylvain).
• Robert Marcus, JPMorgan: "competition outside the U.S." and "pretty sharp pricing"; Executive VP Sylvain: "it's been stable" and "we're taking share" when "we compete with that right product" (Executive VP Sylvain).
• Travis Steed, BofA: "CVS contract lost" and confidence in "10%-plus revenue growth in '27"; President Leach: the contract is "a particular portion of a particular PBM" and announced "a plan to launch a new system called Dexcom Direct"; Executive VP Sylvain sized the PBM as "less than 4% of our U.S. revenue results" and said "we don't expect to have much of a significant impact on our next year financial results" (President Leach; Executive VP Sylvain).
• Jeffrey Johnson, Baird: asked what patient price increase might be and how pharmacy-to-DME switching works; Executive VP Sylvain: "we won't get into specific pricing" but it is "much, much, much higher" and DME co-pay "typically" runs "10% to 20%" (Executive VP Sylvain).
• Joanne Wuensch, Citi: timing for Medicare and GA; President Leach: "We still anticipate hearing back...this year" and coverage "taking effect middle of next year"; on GA, "we're still targeting...launching at the end of next year or early '28" (President Leach).
• Jayson Bedford, Raymond James: distributor deal details; Executive VP Sylvain: "it's not going to impact this year" and it is "our largest remaining distributor market in Europe" (Executive VP Sylvain).

Sentiment Analysis

• Analyst tone was neutral-to-slightly negative on competitive pricing and U.S. access risk, highlighted by repeated payer questions such as "CVS contract lost" and concerns about exclusivity spread (Travis Steed, BofA; Ravi Misra, Truist).
• Management tone was confident in category durability and pricing, including "we are still extremely confident" (President Leach) and "We haven't seen a degradation of pricing" (Executive VP Sylvain), while also acknowledging disruption sensitivity: "we don't like being in these situations for our patients" (Executive VP Sylvain).
• Versus Q2, the current call carried more defensive precision on payer mechanics and mitigation (Dexcom Direct), while Q2 focused more on Investor Day framing and pipeline narratives (President Leach).

Quarter-over-Quarter Comparison

• "second quarter revenue growth of 13%" (President Leach, Q2) shifted to "revenue growth of 11%" (President Leach, Q3), alongside Q3 commentary of U.S. "acceleration" (Executive VP Sylvain).
• International growth decelerated from "19%" in Q2 (Executive VP Sylvain, Q2) to "5%" in Q3 (Executive VP Sylvain, Q3), with Q3 attributing it to "lapping" prior reimbursement wins and expecting normalization "at the start of next year" (Executive VP Sylvain).
• Full-year revenue guidance moved from "$5.18 billion to $5.25 billion" in Q2 (Executive VP Sylvain, Q2) to "$5.20 billion to $5.25 billion" in Q3 (Executive VP Sylvain, Q3); Q3 also announced completion of the prior "$1 billion" 2026 buyback goal and a new "$1 billion" authorization (Executive VP Sylvain).

Risks and Concerns

• "approximately $5 million of incremental foreign exchange headwinds" (Executive VP Sylvain) and international volatility tied to reimbursement timing: "some quarterly variability" (Executive VP Sylvain).
• Payer disruption risk surfaced around a PBM move; management mitigations centered on channel flexibility and support tooling: "Dexcom Direct" to "walk them through every step of the way" (President Leach).
• Manufacturing ramp risk was framed as near-term margin pressure: Ireland turn-on causes "a bit of a step back" and "it usually takes a few quarters" to normalize (Executive VP Sylvain).

Final Takeaway

Management described Q3 as continued share gains and operational progress, pairing 11% revenue growth with higher full-year operating margin guidance and another $1 billion repurchase authorization. The call emphasized upcoming reimbursement catalysts for type 2 non-insulin coverage, expansion of the G7 15 Day transition toward nearly 50% of the U.S. base by year-end, and mitigation plans for payer disruption through the Dexcom Direct service, while flagging short-term international growth variability and Ireland ramp-related margin drag.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.